Guardant Health (GH) Raised to PT $70 at JP Morgan

JPMorgan raised the PT to $70 from $60 and reiterated an Overweight rating on Guardant Health (NASDAQ: GH).

The analyst commented, "Yesterday, we attended Guardant Health’s (GH) analyst day held in New York. Management used the forum to update its 2028 financial targets, now calling for ~$2.2B in 2028 revenue vs. the >$2.0B target given during the 2023 analyst day, translating to a +34% growth CAGR from 2025-2028 (using the midpoint of 2025 guidance of $920M) vs. the prior target of >+30% CAGR from 2023-2028."

For an analyst ratings summary and ratings history on Guardant Health click here. For more ratings news on Guardant Health click here.

Shares of Guardant Health closed at $57.67 yesterday.

You May Also Be Interested In

• Ashland said to explore sale amid takeover interest - Bloomberg
• Bimini Capital Management (BMNM) Tops Q2 EPS by 4c
• First Phosphate ADRs uplisted to Nasdaq Global Market as PHOS